We are live on ! Find out more
ALT icon

Altimmune

158 hedge funds and large institutions have $157M invested in Altimmune in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 57 increasing their positions, 48 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more call options, than puts

Call options by funds: $18.7M | Put options by funds: $14.1M

19% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 48

8% more capital invested

Capital invested by funds: $146M → $157M (+$11M)

0.63% more ownership

Funds ownership: 46.37%47% (+0.63%)

12% less funds holding

Funds holding: 180158 (-22)

45% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 42

Holders
158
Holders Change
-22
Holders Change %
-12.22%
% of All Funds
2.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
57
Reduced
48
Closed
42
Calls
$18.7M
Puts
$14.1M
Net Calls
+$4.55M
Net Calls Change
+$925K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$24M +$4.66M +1,206,514 +23%
BlackRock
2
BlackRock
New York
$24M +$2.7K +699 +0%
State Street
3
State Street
Massachusetts
$13.6M +$3.27M +847,617 +31%
TCM
4
Tang Capital Management
California
$8.04M -$2.39M -618,693 -22%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$7.61M +$319K +82,505 +4%
Two Sigma Investments
6
Two Sigma Investments
New York
$7.53M +$6.02M +1,559,562 +357%
Morgan Stanley
7
Morgan Stanley
New York
$5.62M +$2.53M +655,642 +78%
Two Sigma Advisers
8
Two Sigma Advisers
New York
$5.39M +$5.02M +1,299,200 +1,006%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$5.18M -$948K -245,565 -15%
Citadel Advisors
10
Citadel Advisors
Florida
$4.83M +$2.93M +758,553 +145%
KCM
11
Knoll Capital Management
Florida
$4.23M
Northern Trust
12
Northern Trust
Illinois
$2.48M +$64.4K +16,670 +3%
UBS Group
13
UBS Group
Switzerland
$2.42M -$942K -244,081 -28%
Squarepoint
14
Squarepoint
New York
$2.2M +$2.26M +584,696 New
Goldman Sachs
15
Goldman Sachs
New York
$2.12M +$243K +63,019 +13%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$1.8M +$1.84M +476,926 New
Fidelity Investments
17
Fidelity Investments
Massachusetts
$1.68M +$167K +43,294 +11%
BWCS
18
Beirne Wealth Consulting Services
Connecticut
$1.55M +$263K +68,000 +20%
Millennium Management
19
Millennium Management
New York
$1.39M +$1.12M +289,288 +369%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$1.36M +$1.19M +309,137 +603%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.29M +$38.5K +9,969 +3%
Barclays
22
Barclays
United Kingdom
$1.28M +$186K +48,188 +16%
Bank of America
23
Bank of America
North Carolina
$1.21M -$1.53M -395,579 -55%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$1.12M -$578K -149,681 -33%
Jane Street
25
Jane Street
New York
$1.06M +$1.08M +280,199 New

ALT Hedge Fund Activity: Q3 2025 in Review

158 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2025, worth a combined $157M — up 7.6% from $146M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of ALT and 23 opened new positions — a net loss of 19 holders — while 48 trimmed existing stakes and 57 added.

The largest buyer was Two Sigma Investments, adding an estimated $6.02M. The largest seller was Federated Hermes, cutting an estimated $3.53M.

  • 158 institutional investors held Altimmune (ALT) as of Q3 2025, down from 180 in Q2 2025.
  • Funds reported $157M of Altimmune stock for Q3 2025, up 7.6% quarter-over-quarter.
  • 23 funds opened new Altimmune positions in Q3 2025 and 42 closed out, a net change of -19 holders.
  • The largest Altimmune buyer in Q3 2025 was Two Sigma Investments, an estimated $6.02M added.
  • The largest Altimmune seller in Q3 2025 was Federated Hermes, an estimated $3.53M sold.

Based on aggregated 13F filings for Q3 2025.